ArticleCancers2022
Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer.
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 5 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Pathologic response rates in HER2-low versus HER2-zero early breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis.Breast cancer research : BCR · 2025Pooled it
- Influence of HER2-low and HER2-zero status on pathologic complete response and survival in triple-negative breast cancer: a meta-analysis.Frontiers in oncology · 2025Pooled it
- Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis.World journal of surgical oncology · 2024Pooled it
- Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis.ESMO open · 2023Pooled it
- Clinicopathologic characteristics and prognostic significance of HER2-low expression in patients with early breast cancer: A systematic review and meta-analysis.Frontiers in oncology · 2023Pooled it
- Prognostic Significance of the CPS-EG Score in Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy.Cancers · 2026Article
- Article
- Prevalence of HER2-low status and outcomes in early-stage HER2-negative breast cancer.NPJ breast cancer · 2026Article
- NeoProspect HER2-low: Response and Prognosis After Neoadjuvant Treatment in Patients with HER2-low Breast Cancer.Cureus · 2026Article
- Clinical characteristics and prognostic impact of HER2-ultralow breast cancer and tumor-infiltrating lymphocytes (TILs).BMC cancer · 2025Article
- Differences in Sentinel lymph node biopsy outcomes and prognosis between HER2-low and HER2-zero breast cancer.BMC cancer · 2025Article
- Pathologic Response and Survival Outcomes on HER2-Low vs. HER2-Zero in Breast Cancer Receiving Neoadjuvant Chemotherapy.Medicina (Kaunas, Lithuania) · 2025Article
- Preoperative Differentiation of HER2-Zero and HER2-Low from HER2-Positive Invasive Ductal Breast Cancers Using BI-RADS MRI Features and Machine Learning Modeling.Journal of magnetic resonance imaging : JMRI · 2025Article
- Impact of HER2-Low Status on Pathologic Complete Response and Survival Outcome Among Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy.Journal of breast cancer · 2025Article
- Prognostic impact of HER2-low expression in triple-negative breast cancer of high-grade special histological type and no special type.PloS one · 2025Article
- Clinical Outcomes of CDK4/6 Inhibitor Therapy in HR+/HER2- Metastatic Breast Cancer: A Multicenter Comparison of HER2-Low and HER2-Zero Subgroups.The breast journal · 2025Article
- Impact of Neoadjuvant Therapy on PD-L1 Expression in Triple-Negative Breast Cancer and Correlation with Clinicopathological Factors.Diagnostics (Basel, Switzerland) · 2024Article
- The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study.Scientific reports · 2024Article
- Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy.Scientific reports · 2024Article
- Impact of HER2 status on clinicopathological characteristics and pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer.Breast cancer research and treatment · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeInvestigates the link between HER2 status and histological response after neoadjuvant chemotherapy in patients with early TNBC.
methodsWe retrieved clinical and anatomopathological data retrospectively from 449 patients treated for the first time with standard neoadjuvant chemotherapy for early unilateral BC between 2005 and 2020. The primary endpoint was pathological complete response (pCR, i.e., ypT0 ypN0), according to HER2 status. Secondary endpoints included invasive disease-free survival (I-DFS) and overall survival (OS).
results437 patients were included, and 121 (27.7%) patients had HER2-low tumours. The pCR rate was not significantly different between the HER2-low group vs. the HER2-0 group (35.7% versus 41.8%,
conclusionsIn our cohort, HER2 status was not significantly associated with pCR in a manner consistent with data published recently on TNBC. However, the prognostic impact of HER2-low expression among TNBC patients warrants further evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.